AR056519A1 - 4-feniltetrahidroisoquinolinas sustituidas, composiciones farmaceuticas que las contienen y usos terapeuticos en trastornos renales, respiratorios y otros - Google Patents
4-feniltetrahidroisoquinolinas sustituidas, composiciones farmaceuticas que las contienen y usos terapeuticos en trastornos renales, respiratorios y otrosInfo
- Publication number
- AR056519A1 AR056519A1 ARP060104073A ARP060104073A AR056519A1 AR 056519 A1 AR056519 A1 AR 056519A1 AR P060104073 A ARP060104073 A AR P060104073A AR P060104073 A ARP060104073 A AR P060104073A AR 056519 A1 AR056519 A1 AR 056519A1
- Authority
- AR
- Argentina
- Prior art keywords
- carbon atoms
- hydrogen
- zero
- alkyl
- phenylthethrahyrochinolines
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 230000000241 respiratory effect Effects 0.000 title 1
- 230000001225 therapeutic effect Effects 0.000 title 1
- 125000004432 carbon atom Chemical group C* 0.000 abstract 10
- 239000001257 hydrogen Substances 0.000 abstract 9
- 229910052739 hydrogen Inorganic materials 0.000 abstract 9
- 125000004435 hydrogen atom Chemical class [H]* 0.000 abstract 9
- 125000000217 alkyl group Chemical group 0.000 abstract 5
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 4
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 3
- 239000001301 oxygen Substances 0.000 abstract 3
- 229910052760 oxygen Inorganic materials 0.000 abstract 3
- 229910052757 nitrogen Inorganic materials 0.000 abstract 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical class OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/12—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring
- C07D217/14—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring other than aralkyl radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/14—Ectoparasiticides, e.g. scabicides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Diabetes (AREA)
- Urology & Nephrology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Hematology (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Vascular Medicine (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Dermatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
Abstract
Reivindicacion 1: Un compuesto de formula (1), en donde: R1, R2, R3 y R4, son cada uno, de manera independiente, hidrogeno, F, Cl, Br, I, CN, NO2 o R11-(CmH2m)-An-; m es cero, 1, 2, 3 o 4; n es cero o 1; R11 es hidrogeno, metilo o CpF2p+1; A es oxígeno, NH, N(CH3) o S(O)q; p es 1, 2 o 3; q es cero, 1 o 2; R5 es hidrogeno, alquilo con 1, 2, 3, 4, 5 o 5 átomos de carbono o cicloalquilo con 3, 4, 5, o 6 átomos de carbono; R6 es hidrogeno, OH, F, CF3, alquilo con 1, 2, 3, o 4 átomos de carbono o cicloalquilo con 3, 4, 5 o 6 átomos de carbono; R7 y R8, son cada uno, de manera independiente, hidrogeno, F, Cl, Br, CN, CO2R12, NR13R14 o R16-(CmmH2mm)-Enn-; R12 es hidrogeno, alquilo con 1, 2, 3 o 4 átomos de carbono o cicloaquilo con 3, 4, 5, o 6 átomos de carbono; R13 y R14, son cada uno, de manera independiente, hidrogeno, alquilo con 1, 2, 3 o 4 átomos de carbono o cicloalquilo con 3, 4, 5 o 6 átomos de carbono; o R13 y R14, con el átomo de nitrogeno al que están unidos, forman un anillo de 4, 5, 6 o 7 miembros, en donde un grupo CH2 puede estar reemplazando por NR15, S u oxígeno; R15 es hidrogeno, alquilo con 1, 2, 3, o 4 átomos de carbono o cicloalquilo con 3, 4, 5 o 6 átomos de carbono; mm es cero, 1, 2, 3 o 4; nn es cero o 1; R16 es hidrogeno, metilo o CppF2pp+1; E es oxígeno o S(O)qq; pp es 1, 2 o 3; qq es cero, 1 o 2; y también sus sales y trifluoroacetatos farmacéuticamente aceptables.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE102005044817A DE102005044817A1 (de) | 2005-09-20 | 2005-09-20 | Substituierte 4-Phenyltetrahydroisochinoline, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament, sowie sie enthaltendes Medikament |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR056519A1 true AR056519A1 (es) | 2007-10-10 |
Family
ID=37595895
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP060104073A AR056519A1 (es) | 2005-09-20 | 2006-09-18 | 4-feniltetrahidroisoquinolinas sustituidas, composiciones farmaceuticas que las contienen y usos terapeuticos en trastornos renales, respiratorios y otros |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US8455515B2 (es) |
| EP (1) | EP1928836B1 (es) |
| JP (1) | JP5231229B2 (es) |
| KR (1) | KR101462060B1 (es) |
| CN (1) | CN101268054B (es) |
| AR (1) | AR056519A1 (es) |
| AU (1) | AU2006294136B2 (es) |
| BR (1) | BRPI0616316A2 (es) |
| CA (1) | CA2623462C (es) |
| DE (1) | DE102005044817A1 (es) |
| ES (1) | ES2550141T3 (es) |
| IL (1) | IL189914A (es) |
| MX (1) | MX2008003014A (es) |
| MY (1) | MY150702A (es) |
| PL (1) | PL1928836T3 (es) |
| TW (1) | TWI401247B (es) |
| WO (1) | WO2007033773A1 (es) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE102005044815A1 (de) * | 2005-09-20 | 2007-03-22 | Sanofi-Aventis Deutschland Gmbh | Verwendung von Inhibitoren des Na+/H+ Austauschers, Subtyp 5 (NHE5) zur Gedächtnisverbesserung |
| DE102006012544A1 (de) * | 2006-03-18 | 2007-09-27 | Sanofi-Aventis | Substituierte 1-Amino 4-phenyl-dihydroisochinoline, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament, sowie sie enthaltendes Medikament |
| FR2921935B1 (fr) * | 2007-10-05 | 2011-10-28 | Centre Nat Rech Scient | Procede de criblage de composes utilisables pour le traitement de troubles respiratoires |
| WO2018129556A1 (en) | 2017-01-09 | 2018-07-12 | Ardelyx, Inc. | Compounds and methods for inhibiting nhe-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders |
| US10543207B2 (en) * | 2008-12-31 | 2020-01-28 | Ardelyx, Inc. | Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders |
| EP2384318B1 (en) | 2008-12-31 | 2017-11-15 | Ardelyx, Inc. | Compounds and methods for inhibiting nhe-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders |
| US20120088737A2 (en) * | 2009-10-02 | 2012-04-12 | Ajinomoto Co., Inc | Novel acyl guanidine derivatives |
| HK1211469A1 (en) | 2012-08-21 | 2016-05-27 | Ardelyx, Inc. | Compounds and methods for inhibiting nhe-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders |
| US10376481B2 (en) | 2012-08-21 | 2019-08-13 | Ardelyx, Inc. | Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders |
| NZ752535A (en) | 2013-04-12 | 2022-08-26 | Ardelyx Inc | Nhe3-binding compounds and methods for inhibiting phosphate transport |
| PL3173408T3 (pl) * | 2014-07-25 | 2019-05-31 | Taisho Pharma Co Ltd | Związek fenylotetrahydroizochinolinowy podstawiony heteroarylem |
| US10865185B2 (en) | 2015-08-21 | 2020-12-15 | Srx Cardio, Llc | Composition and methods of use of tetrahydroisoquinoline small molecules to bind and modulate PCSK9 protein activity |
| WO2017034997A1 (en) | 2015-08-21 | 2017-03-02 | Portola Pharmaceuticals, Inc. | Phenylpiperazine proprotein convertase subtilisin/kexin type 9 (pcsk9) modulators and their use |
| WO2017034994A1 (en) | 2015-08-21 | 2017-03-02 | Portola Pharmaceuticals, Inc. | Composition and methods of use of novel phenylalanine small organic compounds to directly modulate pcsk9 protein activity |
| US10363263B2 (en) | 2015-11-04 | 2019-07-30 | Prescient Pharma, Llc | Anti-aging compositions and methods for using same |
| WO2017147328A1 (en) | 2016-02-23 | 2017-08-31 | Portola Pharmaceuticals, Inc. | Compounds for binding proprotein convertase subtilisin/kexin type 9 (pcsk9) |
| WO2018129552A1 (en) | 2017-01-09 | 2018-07-12 | Ardelyx, Inc. | Compounds useful for treating gastrointestinal tract disorders |
| WO2018129557A1 (en) | 2017-01-09 | 2018-07-12 | Ardelyx, Inc. | Inhibitors of nhe-mediated antiport |
| WO2019060051A1 (en) | 2017-08-04 | 2019-03-28 | Ardelyx, Inc. | GLYCYRRHETINIC ACID DERIVATIVES FOR THE TREATMENT OF HYPERKALIEMIA |
| PH12021551892A1 (en) | 2019-02-07 | 2022-08-01 | Ardelyx Inc | Glycyrrhetinic acid derivatives for use in treating hyperkalemia |
| JP2022533251A (ja) | 2019-05-21 | 2022-07-21 | アルデリックス， インコーポレイテッド | 患者において血清リン酸塩を低下させるための組み合わせ |
| US12115154B2 (en) | 2020-12-16 | 2024-10-15 | Srx Cardio, Llc | Compounds for the modulation of proprotein convertase subtilisin/kexin type 9 (PCSK9) |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2111138A1 (en) * | 1993-01-15 | 1994-07-16 | Thierry Godel | Octahydrophenanthrene derivatives |
| AU2001244336A1 (en) * | 2000-03-30 | 2001-10-15 | British Telecommunications Public Limited Company | Data networks |
| DE10019062A1 (de) * | 2000-04-18 | 2001-10-25 | Merck Patent Gmbh | 2-Guanidino-4-aryl-chinazoline als NHE-3 Inhibitoren |
| DK1453810T3 (da) * | 2001-12-05 | 2009-07-20 | Sanofi Aventis Deutschland | Substituerede 4-phenyltetrahydroisoquinoliner, fremgangsmåde til deres fremstilling, deres anvendelse som medikament indeholdende samme |
| DE10163914A1 (de) * | 2001-12-22 | 2003-07-03 | Aventis Pharma Gmbh | Substituierte 4-Phenyltetrahydroisochinolinium-Salze, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament, sowie sie enthaltendes Medikament |
| RS52431B (sr) | 2002-07-25 | 2013-02-28 | Janssen Pharmaceutica N.V. | Derivati hinolina i njihova upotreba kao mikobakterijskih inhibitora |
| DE10312963A1 (de) * | 2003-03-24 | 2004-10-07 | Aventis Pharma Deutschland Gmbh | Substituierte 4-Phenyltetrahydroisochinoline, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament, sowie sie enthaltendes Medikament |
| US7241775B2 (en) * | 2003-03-24 | 2007-07-10 | Sanofi-Aventis Deutschland Gmbh | Composition, process of making, and medical use of substituted 4-phenyltetrahydroisoquinolines |
| DE102004046492A1 (de) * | 2004-09-23 | 2006-03-30 | Sanofi-Aventis Deutschland Gmbh | Substituierte 4-Phenyltetrahydroisochinoline, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament, sowie sie enthaltendes Medikament |
-
2005
- 2005-09-20 DE DE102005044817A patent/DE102005044817A1/de not_active Withdrawn
-
2006
- 2006-09-08 WO PCT/EP2006/008770 patent/WO2007033773A1/de not_active Ceased
- 2006-09-08 AU AU2006294136A patent/AU2006294136B2/en not_active Ceased
- 2006-09-08 CN CN2006800346094A patent/CN101268054B/zh not_active Expired - Fee Related
- 2006-09-08 PL PL06805671T patent/PL1928836T3/pl unknown
- 2006-09-08 JP JP2008531569A patent/JP5231229B2/ja not_active Expired - Fee Related
- 2006-09-08 EP EP06805671.2A patent/EP1928836B1/de not_active Not-in-force
- 2006-09-08 KR KR1020087006830A patent/KR101462060B1/ko not_active Expired - Fee Related
- 2006-09-08 MX MX2008003014A patent/MX2008003014A/es active IP Right Grant
- 2006-09-08 BR BRPI0616316-5A patent/BRPI0616316A2/pt not_active IP Right Cessation
- 2006-09-08 CA CA2623462A patent/CA2623462C/en not_active Expired - Fee Related
- 2006-09-08 ES ES06805671.2T patent/ES2550141T3/es active Active
- 2006-09-08 MY MYPI20080496 patent/MY150702A/en unknown
- 2006-09-18 TW TW095134388A patent/TWI401247B/zh not_active IP Right Cessation
- 2006-09-18 AR ARP060104073A patent/AR056519A1/es not_active Application Discontinuation
-
2008
- 2008-03-04 IL IL189914A patent/IL189914A/en not_active IP Right Cessation
- 2008-03-12 US US12/046,928 patent/US8455515B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| CA2623462A1 (en) | 2007-03-29 |
| JP2009508889A (ja) | 2009-03-05 |
| BRPI0616316A2 (pt) | 2011-06-14 |
| DE102005044817A1 (de) | 2007-03-22 |
| TWI401247B (zh) | 2013-07-11 |
| US8455515B2 (en) | 2013-06-04 |
| ES2550141T3 (es) | 2015-11-04 |
| MX2008003014A (es) | 2008-03-24 |
| EP1928836A1 (de) | 2008-06-11 |
| EP1928836B1 (de) | 2015-07-15 |
| PL1928836T3 (pl) | 2015-12-31 |
| AU2006294136A1 (en) | 2007-03-29 |
| CA2623462C (en) | 2014-08-19 |
| IL189914A0 (en) | 2008-08-07 |
| CN101268054B (zh) | 2012-08-22 |
| TW200806630A (en) | 2008-02-01 |
| US20080194621A1 (en) | 2008-08-14 |
| AU2006294136B2 (en) | 2012-07-05 |
| KR101462060B1 (ko) | 2014-11-17 |
| IL189914A (en) | 2013-08-29 |
| MY150702A (en) | 2014-02-28 |
| WO2007033773A1 (de) | 2007-03-29 |
| HK1124321A1 (en) | 2009-07-10 |
| CN101268054A (zh) | 2008-09-17 |
| JP5231229B2 (ja) | 2013-07-10 |
| KR20080046675A (ko) | 2008-05-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR056519A1 (es) | 4-feniltetrahidroisoquinolinas sustituidas, composiciones farmaceuticas que las contienen y usos terapeuticos en trastornos renales, respiratorios y otros | |
| AR068657A1 (es) | Derivados de piperidina y piperazina | |
| AR081932A1 (es) | Derivados de heteroaril imidazolona, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de enfermedades neoplasicas y autoinmunes | |
| CO5680430A2 (es) | Derivados de 1-benzol-piperazina como inhibidores de la captacion de glicina para el ratamiento de psicosis | |
| AR082153A1 (es) | N-sulfonilbenzamidas utiles como inhibidor del canal de sodio | |
| AR067478A1 (es) | Compuestos derivados de morfolina pirimidina | |
| AR065863A1 (es) | Derivados de imidazolidinona | |
| AR049291A1 (es) | Derivados de pirazol, composiciones que contienen dichos compuestos y procedimientos de uso | |
| AR069796A1 (es) | Derivados de bencimidazol, sustituido por carboxilo o por hidroxilo, proceso para prepararlos y composiciones farmaceuticas que los contienen | |
| AR063028A1 (es) | Derivados heterociclicos de piridin-2-carboxamida activadores de glucoquinasas, utiles para el tratamiento de diabetes y obesidad y composiciones farmaceuticas que los contienen. | |
| PA8795301A1 (es) | Derivados de 1,2,4,5-tetrahidro-3h-benzazepinas, su procedimiento de preparacion y las composiciones farmaceuticas que las contienen | |
| AR055165A1 (es) | Inhibidores ns5b de vhc de indolobenzacepina, composiciones farmaceuticas que los contienen y su uso en el tratamiento de la hepatitis c. | |
| AR059184A1 (es) | Derivados de sulfonamidas, su preparacion y su aplicacion en tarapeutica | |
| AR055878A1 (es) | Derivados de ciclopropanocarboxamida | |
| PA8852101A1 (es) | Nucleótidos uracil ciclopropílicos | |
| TNSN06203A1 (en) | Derivatives of n- (1,5-diphenyl-1h-pyrazol-3-yl) sulphonamide with cb1 receptor affinity | |
| BRPI0513777A (pt) | composto ou um sal do mesmo, composição farmacêutica, e, uso de um composto ou de um sal do mesmo | |
| AR060812A1 (es) | Moduladores de receptores metabotropicos de glutamato mglur5, composiciones farmaceuticas que los contienen y usos en procesos patofisiologicos y trastornos que afectan el scn | |
| AR073043A1 (es) | Compuestos de azetidinas polisustituidos, composiciones farmaceuticas que los contienen, metodo de preparacion y uso de los mismos en el tratamiento de enfermedades respiratorias, metabolicas y del sistema nervioso central, entre otras. | |
| AR077534A1 (es) | Derivados de isoxazol, un proceso para su obtencion, composiciones farmaceuticas que los contienen y su uso en el tratamiento de enfermedades relacionadas con el receptor gaba aalfa5 | |
| AR094123A1 (es) | Compuesto triciclicos | |
| AR054212A1 (es) | Derivados de bisarilurea sustituidos con heterociclos, composicion farmaceutica y un metodo para prepararla y compuestos intermediarios de sintesis | |
| MX2009012383A (es) | Derivados de arilamida pirimidona para el tratamiento de enfermedades neurodegenerativas. | |
| CO6290668A2 (es) | Derivados de 1-oxo-1,2-dihidroisoquinolein-5-carboxamidas y de 4-oxo-3,4-dihifroquinazolina -8-carboxamidas su preparacion y su aplicacion en terapeutica | |
| AR053326A1 (es) | 4 - feniltetrahidroisoquinolinas sustituidas, su uso en la preparacion de un medicamento para el tratamiento de enfermedades mediadas por la activacion de nhe y composicion farmaceutica que las comprende. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |